Effect of Pre-Transplant Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma Patients With Liver Transplantation

Based on the follow-up data of hepatocellular carcinoma (HCC) patients undergoing liver transplantation from the China Liver Transplant Registry (CLTR) and the First Affiliated Hospital of Xi'an Jiaotong University, patients who met the inclusion criteria were assessed for tumor response, post-transplant tumor recurrence, and survival rates. Statistical analysis was performed to evaluate patient prognosis and to identify risk factors affecting outcomes.

NCT Number	NCT07418138
Lead Sponsor	Hu Liangshuo
Conditions	Liver Transplantation, Hepatocellular Carcinoma (HCC), Tyrosine Kinase Inhibitor, Survival Rate
Enrollment	484 participants
Start Date	2015-01-01
Primary Completion	2024-12-31 (estimated)
Study Completion	2024-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-02-18